With a projected global Prosthetic Heart Valve Market size of US$ 13,234.9 million by 2023, the industry is anticipated to advance rapidly. By 2033, the prosthetic heart valve market is expected to be valued at US$ 27,277.6 million.
The prosthetic heart valve sales are set to rise through 2033 at a CAGR of 7.5% due to the increased prevalence of valvular illnesses like tricuspid regurgitation, idiopathic and ischemic mitral regurgitation, and aortic stenosis.
| Attributes | Details |
|---|---|
| Market Value for 2023 | US$ 13,234.9 million |
| Market Value for 2033 | US$ 27,277.6 million |
| Market CAGR from 2023 to 2033 | 7.5% |
Catalysts for Market Growth of Prosthetic Heart Valve
Innovative Opportunities in the Prosthetic Heart Valve Sector
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Artificial Heart Valve Market Overview from 2018 to 2022
| Historical CAGR | 11.9% |
|---|---|
| Forecast CAGR | 7.5% |
Predictions and Potential Developments from 2023 to 2033
Roadblocks Faced by Prosthetic Heart Valve Manufacturers
Healthcare delivery and pricing structures are continually changing. Manufacturers of prosthetic heart valves must adjust to changing economic situations, payment policies, and healthcare delivery paradigms
An extensive artificial heart valve market segmentation evaluation sums up this part of the study. The prosthetic heart valve providers are paying more significant consideration to market trends in heart valve prosthetics and demand for biological/tissue heart valves. The hospital segment monopolizes the end-user category of the prosthetic heart valve demand.
Biological or tissue heart valves continue to be in high demand in the prosthetic heart valve sector. The biological or tissue heart valves provide a more natural and biocompatible option to reduce the risk of blood clot development and the requirement for long-term anticoagulant therapy.
A significant factor in the continued demand for tissue heart valves is the aging global population and the rising prevalence of cardiac disorders. The longevity and lower incidence of problems with biological valves make them a preferred choice for older patients who frequently need valve replacement.
| Leading Segment | Biological/Tissue Heart Valves |
|---|---|
| Segment Share | 42.3% |
Biological heart valves are a more reliable long-term solution owing to improved tissue engineering and preservation procedures that have increased their durability and performance. The strong demand for biological heart valves in the prosthetic heart valve devices market results from the field's ongoing research and development activities, which are helping to broaden their applications.
The hospitals are the dominant end user, accounting for a substantial 75.6% market share of prosthetic heart valves. The hospital sector has a priceless infrastructure that includes advanced medical equipment, modern surgical facilities, and a variety of diagnostic instruments, producing a setting favorable to challenging cardiac treatments.
| Leading Segment | Hospitals |
|---|---|
| Segment Share | 75.6% |
The choice of patients to receive their treatments in hospitals is fueling the expansion of the hospital segment. Hospitals are the first choice of people seeking prosthetic heart valve treatments due to their excellent reputation, accessibility, and wide range of healthcare services. Between 2023 and 2033, the hospital sector has the opportunity to keep control of the prosthetic heart valve demand.
Principal Consultant
This part examines an exhaustive market analysis with data about various nations. In North America, Europe, and Asia Pacific, prosthetic heart valve sales are strengthening. North America has been developing steadily, followed by Europe, but prosthetic heart valve manufacturers possess ample opportunity in Asia Pacific.
| Attributes | Details |
|---|---|
| United States - Market Share | 36% |
| Attributes | Details |
|---|---|
| Germany - Market Share | 8.8% |
| United Kingdom - Market CAGR | 12.4% |
| Attributes | Details |
|---|---|
| Japan - Market Share | 5.8% |
| China - Market CAGR | 12.5% |
| India - Market CAGR | 12.2% |
Due to the aging population and the increased prevalence of cardiac illnesses, there is fierce rivalry in the sales of prosthetic heart valves. Prominent prosthetic heart valve manufacturers dominate the industry with a broad selection of products. Key research areas include advancements in biocompatibility, robustness, and minimally invasive methods.
New prosthetic heart valve suppliers are introducing modern technologies, and expanding markets in the Asia Pacific have room for expansion. Critical market share variables for prosthetic heart valves include cost-effectiveness, regulatory approvals, and market penetration techniques. The intense competition encourages constant innovations in artificial cardiac valve devices and better patient results.
Recent Advancements
| Company | Details |
|---|---|
| The Approval to Edwards Lifesciences | The MITRIS RESILIA valve was approved by the United States Food and Drug Administration (FDA) in March 2022. It is a tissue valve replacement made especially for the mitral location of the heart. |
| Jenavalve Technology, Inc. formed a Strategic Investment with Peijia Medical Limited. | With the Chinese company Peijia Medical Limited, JenaValve Technology, Inc. engaged in a strategic investment and exclusive technology licensing deal in January 2022. In return for exclusive rights to create and market JenaValve's cutting-edge Trilogy TAVR systems in the Greater China region to treat patients with either severe symptomatic aortic regurgitation (AR) or severe symptomatic aortic stenosis, Peijia has invested cash and equity in JenaValve and continues to do so. |
| FDA Approval for Abbott | For its Epic Plus and Epic Plus Supra Stended Tissue Valves, Abbott received FDA approval in 2021. The approval could be helpful in the management of mitral and aortic valve diseases. |
| Spectrum Health and Medtronic Plc Made the Partnership Announcement | To add value to healthcare and improve outcomes for Spectrum Health patients, Medtronic plc and Spectrum Health inked a collaboration agreement in 2021. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market to secure a valuation of US$ 13,234.9 million in 2023.
The market is estimated to reach US$ 27,277.6 million by 2033.
Through 2033, the industry is anticipated to expand at a 7.5% CAGR.
From 2018 to 2022, the sales of prosthetic heart valves registered an 11.9% CAGR.
The biological/tissue heart valve sector is set to achieve a 42.3% market share.
A 75.6% market share is expected for the hospital sector.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Product, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Product, 2023 to 2033 5.3.1. Mechanical Heart Valves 5.3.1.1. Mechanical Aortic Valve 5.3.1.2. Mechanical Mitral Valve 5.3.2. Biological/Tissue Heart Valves 5.3.2.1. Tissue Aortic Valve 5.3.2.2. Tissue Mitral Valve 5.3.3. Transcatheter Heart Valves 5.3.3.1. Transcatheter Aortic Valve 5.3.3.2. Transcatheter Mitral Valve 5.4. Y-o-Y Growth Trend Analysis By Product, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Product, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033 6.3.1. Hospitals 6.3.2. Ambulatory Services 6.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Western Europe 7.3.4. Eastern Europe 7.3.5. South Asia and Pacific 7.3.6. East Asia 7.3.7. Middle East and Africa 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1.USA 8.2.1.2. Canada 8.2.2. By Product 8.2.3. By End User 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Product 8.3.3. By End User 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Product 9.2.3. By End User 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Product 9.3.3. By End User 9.4. Key Takeaways 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2.UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Western Europe 10.2.2. By Product 10.2.3. By End User 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Product 10.3.3. By End User 10.4. Key Takeaways 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Poland 11.2.1.2. Russia 11.2.1.3. Czech Republic 11.2.1.4. Romania 11.2.1.5. Rest of Eastern Europe 11.2.2. By Product 11.2.3. By End User 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Product 11.3.3. By End User 11.4. Key Takeaways 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Bangladesh 12.2.1.3. Australia 12.2.1.4. New Zealand 12.2.1.5. Rest of South Asia and Pacific 12.2.2. By Product 12.2.3. By End User 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Product 12.3.3. By End User 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Product 13.2.3. By End User 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Product 13.3.3. By End User 13.4. Key Takeaways 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Product 14.2.3. By End User 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Product 14.3.3. By End User 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. USA 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Product 15.1.2.2. By End User 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Product 15.2.2.2. By End User 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Product 15.3.2.2. By End User 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Product 15.4.2.2. By End User 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Product 15.5.2.2. By End User 15.6.UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Product 15.6.2.2. By End User 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Product 15.7.2.2. By End User 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Product 15.8.2.2. By End User 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Product 15.9.2.2. By End User 15.10. Poland 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Product 15.10.2.2. By End User 15.11. Russia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Product 15.11.2.2. By End User 15.12. Czech Republic 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Product 15.12.2.2. By End User 15.13. Romania 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Product 15.13.2.2. By End User 15.14. India 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Product 15.14.2.2. By End User 15.15. Bangladesh 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Product 15.15.2.2. By End User 15.16. Australia 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Product 15.16.2.2. By End User 15.17. New Zealand 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Product 15.17.2.2. By End User 15.18. China 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Product 15.18.2.2. By End User 15.19. Japan 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Product 15.19.2.2. By End User 15.20. South Korea 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Product 15.20.2.2. By End User 15.21. GCC Countries 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Product 15.21.2.2. By End User 15.22. South Africa 15.22.1. Pricing Analysis 15.22.2. Market Share Analysis, 2022 15.22.2.1. By Product 15.22.2.2. By End User 15.23. Israel 15.23.1. Pricing Analysis 15.23.2. Market Share Analysis, 2022 15.23.2.1. By Product 15.23.2.2. By End User 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Product 16.3.3. By End User 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Edward Lifesciences Corporation 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. St. Jude Medical, Inc 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Medtronic plc 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Boston Scientific Corporation 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Abbott Laboratories 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. SYMETIS 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. LivaNova PLC 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. CryoLife, Inc. 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Braile Biomedica 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. Colibri Heart Valve LLC 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Prosthetic Heart Valve Market
